Handelsavisen
prelaunch
Companies Health Care COR.V
CO
COR.V TSX Venture Diversified Pharmaceuticals

Camino Minerals Corp

$0,51
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
ROE
-15,0 %
Net margin
Debt / equity
0,01
Beta
52w range
Volume
3,2k
Day range
$284,23–$289,78
Prev close
$284,47
Open
$285,85
Next earnings
Ex-dividend
TR 1Y
About

Camino Minerals Corp is a Canadian-based company engaged in the exploration and development of mineral resources, primarily focused on specialty mining and metals.

Business. Camino Minerals Corp (COR.V) is a diversified pharmaceuticals company listed on the TSX Venture Exchange. The firm operates within the Health Care sector, focusing on the development and production of pharmaceutical products. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the diversified pharmaceuticals market.

Classification99 %
SectorHealth Care
Industry groupDiversified Pharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-15,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning COR.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,7 %+1,5 %
    Communication Services+2,2 %−5,5 %+1,5 %
    Energy+0,9 %+5,2 %+0,1 %
    Health Care · THIS SECTOR+0,7 %−0,8 %−0,1 %
    Information Technology+0,2 %+8,0 %−0,5 %
    Consumer Discretionary+0,2 %+8,8 %−0,6 %
    Financials−0,3 %−2,8 %−1,0 %
    Consumer Staples−0,6 %+2,2 %−1,3 %
    Real Estate−0,7 %+10,9 %−1,5 %
    Industrials−1,1 %−0,3 %−1,9 %
    Utilities−1,9 %+28,2 %−2,6 %

    Developing storylines

    No tracked sagas currently linked to COR.V. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-07-26 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR
    • Congressional trades
    • CongressJared Moskowitz — Cencora, Inc. Common Stock2026-05-06 · Democrat · FL · Sale · $1,001 - $15,000
    • CongressJared Moskowitz — Cencora, Inc. Common Stock2026-03-23 · Democrat · FL · Purchase · $1,001 - $15,000
    • CongressGreg Landsman — Cencora, Inc. Common Stock2025-03-27 · Democrat · OH · Sale · $15,001 - $50,000
    • CongressGreg Landsman — Cencora, Inc. Common Stock2024-05-29 · Democrat · OH · Purchase · $15,001 - $50,000

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Camino Minerals Corp (COR.V) is a diversified pharmaceuticals company listed on the TSX Venture Exchange. The firm operates within the Health Care sector, focusing on the development and production of pharmaceutical products. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the diversified pharmaceuticals market.

    Classification99 %
    SectorHealth Care
    Industry groupDiversified Pharmaceuticals
    AI synthesis
    GENERATED

    Camino Minerals Corp maintains a strong liquidity position with CAD 1,092,480 in cash and equivalents, supported by a current ratio of 1.24, indicating the company can cover its short-term liabilities with its current assets. The company's debt-to-equity ratio is 0.01, reflecting a conservative capital structure with minimal long-term debt obligations. However, the company reported negative operating and free cash flows of CAD -1,772,620 and CAD -742,500, respectively, indicating ongoing cash burn.

    The company's profitability metrics are weak, with a return on equity (ROE) of -15.05% and a return on assets (ROA) of -11.88%, both significantly below the industry median for specialty mining and metals. These negative returns suggest the company is not generating value for shareholders or effectively utilizing its assets to generate profit.

    Camino Minerals Corp does not disclose segment or geographic revenue breakdowns in its latest financial filings, making it difficult to assess revenue concentration or geographic exposure. The absence of such data limits the ability to evaluate the company's diversification and potential regional risks.

    The company's growth trajectory is currently constrained, with no disclosed revenue growth or expansion plans in the latest financial reports. The lack of positive revenue history and forward-looking guidance suggests the company is in an early or exploratory phase, with limited visibility on future performance.

    The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt load and strong cash position reduce the likelihood of near-term financial distress. However, the negative cash flows and weak profitability metrics suggest the company may need to raise additional capital in the future, which could lead to dilution for existing shareholders.

    Recent filings and transcripts do not highlight any major events or strategic shifts for Camino Minerals Corp. The company appears to be in a holding pattern, with no significant operational or financial developments reported in the latest available data.

    Key takeaways
    • Camino Minerals Corp has a strong liquidity position with CAD 1.09 million in cash and a current ratio of 1.24.
    • The company's profitability is weak, with a ROE of -15.05% and ROA of -11.88%, indicating poor returns for shareholders and asset utilization.
    • No segment or geographic revenue data is disclosed, limiting visibility into the company's diversification and regional exposure.
    • The company is in a growth-constrained phase with no disclosed revenue growth or expansion plans.
    • Low liquidity and dilution risk are reported, but the company's negative cash flows suggest potential future capital needs.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation FY

    Market price
    $0,51
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $5.0M
    Net cash
    $1.1M
    Current ratio
    1.2
    Debt / equity
    0.0
    ROA
    -11.9%
    ROE
    -15.0%
    Cash conversion
    238.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryDiversified Pharmaceuticals1 042,4B node revenueMCK 38,7%COR 30,8%CAH 21,4%DB 3,4%REGN 1,4%BIIB 0,9%ZTS 0,9%GRFS 0,8%Other 1,7%
    Source: company disclosures · own-taxonomy revenue-covered set · attribution: collision-suspect (indicative)COR 30,8% · rank #2 of 40

    Business relationships

    Business relationships22 disclosed relationships · 1 type · extracted from filings & disclosures
    Subsidiaries22
    EX21:1cd52da3806aEX21:1cd52da3806aSubsidiarie97%
    EX21:223d659d575bEX21:223d659d575bSubsidiarie97%
    EX21:327f293b7dabEX21:327f293b7dabSubsidiarie97%
    EX21:3cc24092e22aEX21:3cc24092e22aSubsidiarie97%
    EX21:58241672588dEX21:58241672588dSubsidiarie97%
    EX21:6cddc329e863EX21:6cddc329e863Subsidiarie97%
    EX21:7041eeafd871EX21:7041eeafd871Subsidiarie97%
    EX21:78120bb30b09EX21:78120bb30b09Subsidiarie97%
    EX21:7b76b912496fEX21:7b76b912496fSubsidiarie97%
    EX21:8168ff02786cEX21:8168ff02786cSubsidiarie97%
    EX21:9488b18073aeEX21:9488b18073aeSubsidiarie97%
    EX21:b332cbf597c4EX21:b332cbf597c4Subsidiarie97%
    EX21:c118fcd3ef37EX21:c118fcd3ef37Subsidiarie97%
    EX21:cc11d7a16569EX21:cc11d7a16569Subsidiarie97%
    EX21:d30e4f264aceEX21:d30e4f264aceSubsidiarie97%
    EX21:db8405f99635EX21:db8405f99635Subsidiarie97%
    EX21:dcd132625e4eEX21:dcd132625e4eSubsidiarie97%
    EX21:e5b1e7808535EX21:e5b1e7808535Subsidiarie97%
    EX21:eaeca89c62c1EX21:eaeca89c62c1Subsidiarie97%
    EX21:f754fdf2f311EX21:f754fdf2f311Subsidiarie97%
    EX21:f87b79418aa0EX21:f87b79418aa0Subsidiarie97%
    EX21:f97e9957c95eEX21:f97e9957c95eSubsidiarie97%

    Supply chain

    — missing data

    Peer comparison

    Peer comparison7 peers · vs COR · multiples and returns
    MC
    MCK
    Mckesson Corp
    $824,49
    102,3B USD
    P/E
    21,2x
    -14,3 vs self
    Div yield
    0,4 %
    -0,3 vs self
    ROE
    -219,2 %
    -322,3 vs self
    CA
    CAH
    Cardinal Health Inc
    $225,98
    54,7B USD
    P/E
    36,7x
    +1,2 vs self
    Div yield
    0,9 %
    +0,1 vs self
    ROE
    -55,9 %
    -159,0 vs self
    DB
    DB
    DB.V
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    RE
    REGN
    REGENERON PHARMACEUTICALS, INC.
    $651,91
    70,2B USD
    P/E
    15,6x
    -20,0 vs self
    Div yield
    vs self
    ROE
    14,3 %
    -88,7 vs self
    BI
    BIIB
    BIOGEN INC.
    $201,80
    29,6B USD
    P/E
    21,3x
    -14,2 vs self
    Div yield
    vs self
    ROE
    7,5 %
    -95,5 vs self
    ZT
    ZTS
    Zoetis Inc
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    GR
    GRFS
    Grifols SA
    $8,05
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE-15,0 %Below median
    D/E0,01Above median
    Cash Conv2,38Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • Camino Minerals Corp Market data — financials · 2026-05-27

    Ownership & reference

    Leadership

    • Jay ChmelauskasPresident, Chief Executive Officer, Director

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    COR.VCanonical
    TSX Venture · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.
    Relationship graph
    COREX21:1cdEX21:223EX21:327EX21:3ccEX21:582EX21:6cdEX21:704EX21:781EX21:7b7EX21:816Diversified Ph
    This companySectorSubsidiaries

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-07-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: political_trade_signal (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-30INSIDERBattaglia Silvana transacted 58 sh — Executive Vice President ~$14k
    2026-06-30INSIDERCampbell Elizabeth S transacted 50 sh — Executive Vice President ~$12k
    2026-06-29INSIDERBoratto Eva C acquired 21.3k sh Restricted Stock Units — Chief Financial Officer
    2026-06-23 03:11 UTCHOLDER1 institutional position change flagged (1 major)
    2026-06-22 00:00 UTCINSIDER2 insider transactions — 2026-06 · net buy $1.2M
    2026-06-22 00:00 UTCINSIDER2 insider transactions — 2026-06 · net buy $1.2M
    2026-06-22INSIDERTyler Lauren M bought 550 sh — Director ~$149k
    2026-06-21 02:57 UTCHOLDER1 institutional position change flagged (1 major)
    2026-06-18INSIDERDURCAN DERMOT MARK bought 4.0k sh — Director ~$1.10M
    2026-06-15FILINGFORM 8-K →
    2026-05-31CONGRESSJared Moskowitz (house) sale shares → $1,001 - $15,000
    2026-05-29FILINGFORM 8-K →
    2026-05-28 00:00 UTCINSIDER4 insider transactions — 2026-05 · net buy $1.2M
    2026-05-28 00:00 UTCINSIDER4 insider transactions — 2026-05 · net buy $1.2M
    2026-05-28INSIDERDURCAN DERMOT MARK bought 4.0k sh — Director ~$1.07M
    2026-05-06FILING10-Q filing →
    2026-05-06FILING8-K filing →
    2026-05-01INSIDERTyler Lauren M transacted 99 sh — Director ~$30k
    2026-05-01INSIDERNALLY DENNIS M transacted 116 sh — Director ~$35k
    2026-05-01INSIDERCooper Ellen transacted 99 sh — Director ~$30k
    2026-04-01 00:00 UTCINSIDER1 insider transaction — 2026-04 1 derivative
    2026-04-01 00:00 UTCINSIDER1 insider transaction — 2026-04 1 derivative
    2026-04-01INSIDERKrikorian Lazarus acquired 3.9k sh Restricted Stock Units — SVP & Chief Accounting Officer
    2026-03-31CONGRESSJared Moskowitz (house) purchase shares → $1,001 - $15,000
    2026-03-23FILINGFORM 8-K →
    2026-03-17FILINGFORM 8-K →
    2026-03-11 00:00 UTCINSIDER19 insider transactions — 2026-03 · net sell $3.1M 3 derivative
    2026-03-11 00:00 UTCINSIDER19 insider transactions — 2026-03 · net sell $3.1M 3 derivative
    2026-03-11INSIDERCleary James F transacted 12.6k sh — Chief Financial Officer
    2026-03-11INSIDERCampbell Elizabeth S transacted 5.8k sh — Executive Vice President ~$2.05M
    2026-03-11INSIDERCampbell Elizabeth S transacted 12.6k sh — Executive Vice President
    2026-03-11INSIDERBattaglia Silvana transacted 3.7k sh — Executive Vice President ~$1.29M
    2026-03-11INSIDERBattaglia Silvana transacted 8.4k sh — Executive Vice President
    2026-03-11INSIDERCleary James F transacted 5.4k sh — Chief Financial Officer ~$1.89M
    2026-03-11INSIDERCleary James F disposed of 12.6k sh Restricted Stock Units — Chief Financial Officer
    2026-03-11INSIDERCampbell Elizabeth S disposed of 12.6k sh Restricted Stock Units — Executive Vice President
    Showing the 40 most recent of 62 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-07-26 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage